Melanoma m1: Diagnosis and therapy

Marco Rastrelli, Saveria Tropea, Jacopo Pigozzo, Elisabetta Bezzon, Luca Giovanni Campana, Roberto Stramare, Mauro Alaibac, Carlo Riccardo Rossi

Research output: Contribution to journalArticle

Abstract

This article reviews the epidemiology, pathogenesis, diagnosis, prognostic factors and treatment of metastatic melanoma, including the most recent developments in the specific field. It examines the sequential and non-linear models of development and progression of melanoma and the main molecular disorder involved in these processes. Clinical and diagnostic aspects have been divided according to clinical staging. Surgical resectability, the site and number of metastases, the number of involved organs, the duration of remission, serum lactate dehydrogenase levels and tumor doubling-time have the greatest prognostic value. Surgical treatment has been analyzed considering its rational function and examining all sites involved in metastasis. We also discuss the palliative role of radiotherapy in relation to various metastatic sites, chemotherapy and recently introduced targeted-therapy. The association of newer drugs and new biological therapies such as ipilimumab and verumafenib have improved the treatment landscape of stage IV melanoma.

Original languageEnglish
Pages (from-to)273-285
Number of pages13
JournalIn Vivo
Volume28
Issue number3
Publication statusPublished - 2014

Keywords

  • Chemotherapy
  • Radiotherapy
  • Review
  • Stage IV melanoma
  • Surgery
  • Tumor doubling-time

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Melanoma m1: Diagnosis and therapy'. Together they form a unique fingerprint.

  • Cite this

    Rastrelli, M., Tropea, S., Pigozzo, J., Bezzon, E., Campana, L. G., Stramare, R., Alaibac, M., & Rossi, C. R. (2014). Melanoma m1: Diagnosis and therapy. In Vivo, 28(3), 273-285.